bendamustine plus rituximab

DRUG2 trials

Sponsors

University of Giessen, Seoul National University Hospital

Conditions

Mantle Cell LymphomaMarginal Zone B-cell LymphomaNon-Hodgkin's Lymphoma

Phase 2

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

CompletedNCT02433795

Seoul National University HospitalMarginal Zone B-cell Lymphoma

Start: 2015-05-01End: 2019-10-01Updated: 2026-04-22

Phase 3

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

CompletedNCT01456351

University of GiessenMantle Cell Lymphoma, Non-Hodgkin's Lymphoma

Start: 2003-09-30End: 2010-12-31Updated: 2024-08-22

Related Papers

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.

2015-12-05112 citations